- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Jane F. Barlow on How Curative, High-Cost Therapies Will Affect Patient OOP Costs
Jane F. Barlow, MD, MPH, MBA, senior advisor, Center for Biomedical Innovation at Massachusetts Institute of Technology, discusses how curative, high-cost therapies will impact patient out-of-pocket (OOP) costs and cost sharing.
Jane F. Barlow, MD, MPH, MBA, senior advisor, Center for Biomedical Innovation at Massachusetts Institute of Technology, discusses how curative, high-cost therapies will impact patient out-of-pocket costs and cost sharing.
TranscriptHow have curative, high-cost therapies impacted patient out-of-pocket costs and cost sharing?
Well, for most of these conditions, patients already have very high out-of-pocket costs. We’ve moved, in this country, to a lot of high-deductible plans and have high maximum out of pockets. So, most of these patients, I believe, will already meet their out-of-pocket maximum. So, whether they have an expensive treatment over time or they have one very high-cost treatment, I’m not sure it’s going to make a difference for the member in that year of treatment.
I think the real question is how does this sort of net out for them over time, is one piece, and whether their costs will be less in future years than it would have been if they were having other treatment or they had chronic costs. Or you know, the other question is, just the affordability in general. So, if patients choose not to get this new therapy because they just look at the overall cost and say it’s too much and they forgo therapy all together, that won’t be a good thing either. So, I think it’s a piece that has to be addressed, but it’s a broader issue than just the gene therapies.
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Zanubrutinib Shows Durable Benefit for High-Risk CLL/SLL at 5 Years in SEQUOIA Trial
June 6th 2025Zanubrutinib showed long-term efficacy in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and deletion of the 17p chromosome, with progression-free survival similar to patients without high-risk disease characteristics.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS
June 5th 2025Patients with myelodysplastic syndrome (MDS) who received luspatercept showed greater hemoglobin gains and transfusion independence compared with erythropoiesis-stimulating agents (ESAs) in a real-world analysis.
Read More
At EHA 2025, Hematology Discussions Will Stretch Across Lifespans and Locations
June 5th 2025The 2025 European Hematology Association (EHA) Congress, convening virtually and in Milan, Italy, from June 12 to June 15, 2025, will feature a revamped program structure for the meeting’s 30th anniversary while maintaining ample opportunities to network, debate, and absorb practice-changing findings in hematology and oncology.
Read More
